Lauren A Byers Selected Research

Neoplasms (Cancer)

2/2024	Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
1/2024	Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
11/2023	BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
11/2023	Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
1/2023	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
1/2023	Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
5/2022	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.
1/2022	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
11/2021	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.
10/2021	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lauren A Byers Research Topics

Disease

49	Neoplasms (Cancer) 02/2024 - 04/2011
21	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2024 - 11/2013
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 02/2007
17	Lung Neoplasms (Lung Cancer) 11/2023 - 08/2013
7	Neoplasm Metastasis (Metastasis) 11/2023 - 10/2014
7	Squamous Cell Carcinoma of Head and Neck 12/2020 - 04/2011
6	Adenocarcinoma of Lung 05/2022 - 08/2015
3	Carcinogenesis 11/2022 - 01/2012
3	Bites and Stings (Sting) 11/2021 - 01/2019
2	Disease Progression 01/2024 - 01/2019
2	Adenocarcinoma 03/2021 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 05/2019
2	Sarcoma (Soft Tissue Sarcoma) 01/2019 - 02/2012
2	Thrombocytopenia (Thrombopenia) 01/2019 - 01/2017
2	Hypersensitivity (Allergy) 01/2018 - 08/2013
2	Breast Neoplasms (Breast Cancer) 04/2017 - 11/2013
2	Head and Neck Neoplasms (Head and Neck Cancer) 09/2016 - 04/2011
2	Hypoxia (Hypoxemia) 08/2011 - 02/2007
1	Dermatitis 01/2023
1	Hepatitis 01/2023
1	Pneumonia (Pneumonitis) 01/2023
1	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2021
1	COVID-19 03/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020

Drug/Important Bio-Agent (IBA)

17	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2011
17	Proteins (Proteins, Gene)FDA Link 11/2021 - 04/2011
8	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2016
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 11/2013
6	PlatinumIBA 11/2023 - 08/2011
4	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 01/2019
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2017
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2021 - 01/2019
4	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2017
4	Messenger RNA (mRNA)IBA 01/2020 - 07/2014
4	Phosphotransferases (Kinase)IBA 01/2018 - 08/2013
3	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 01/2019
3	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2017
3	Immunoconjugates (Immunoconjugate)IBA 11/2022 - 01/2017
3	LigandsIBA 11/2022 - 01/2016
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2022 - 01/2021
3	talazoparibIBA 01/2021 - 11/2013
3	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2012
2	atezolizumabIBA 02/2024 - 12/2023
2	Transcription Factors (Transcription Factor)IBA 09/2021 - 08/2015
2	NucleotidesIBA 01/2021 - 08/2013
2	veliparibIBA 01/2021 - 01/2019
2	B7-H1 AntigenIBA 01/2021 - 12/2019
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 08/2013
2	ChemokinesIBA 01/2020 - 01/2019
2	pyrimidineIBA 05/2019 - 01/2017
2	rovalpituzumab tesirineIBA 09/2017 - 01/2017
2	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 05/2012
2	ErbB Receptors (EGF Receptor)IBA 11/2014 - 02/2007
2	MicroRNAs (MicroRNA)IBA 10/2014 - 07/2014
2	AntibodiesIBA 05/2014 - 04/2011
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2011 - 02/2007
1	Small Cytoplasmic RNAIBA 02/2024
1	Cell-Free Nucleic AcidsIBA 01/2024
1	amivantamab-vmjwIBA 11/2023
1	osimertinibIBA 11/2023
1	AntigensIBA 09/2023
1	venetoclaxIBA 01/2023
1	AZD2811IBA 01/2023
1	anti-thyroglobulinIBA 01/2023
1	IpilimumabIBA 01/2023
1	NivolumabIBA 01/2023
1	Immunoglobulin G (IgG)IBA 01/2023
1	Immunoglobulin M (IgM)IBA 01/2023
1	Keratin-19 (Keratin 19)IBA 01/2023
1	Aurora Kinase BIBA 01/2023
1	Notch ReceptorsIBA 11/2022
1	HM781-36BIBA 11/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	RNA Helicases (RNA Helicase)IBA 01/2022
1	PM 01183IBA 11/2021
1	ceralasertibIBA 11/2021
1	berzosertibIBA 11/2021
1	Interleukin-22 (IL-22)IBA 10/2021
1	Interleukin-17 (Interleukin 17)IBA 10/2021
1	CytokinesIBA 10/2021
1	PFK158IBA 09/2021
1	Peptide Hydrolases (Proteases)FDA Link 03/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	GuanosineIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	c-Mer Tyrosine KinaseIBA 01/2021
1	Inosine Monophosphate (IMP)IBA 01/2021
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2021
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2021
1	Guanosine Triphosphate (GTP)IBA 01/2021
1	EnzymesIBA 01/2021
1	Adenosine (Adenocard)FDA LinkGeneric 01/2021
1	CollagenIBA 01/2020
1	Cyclic GMPIBA 01/2020

Therapy/Procedure

28	Therapeutics 01/2024 - 08/2011
11	Drug Therapy (Chemotherapy) 11/2023 - 08/2011
11	Immunotherapy 01/2023 - 01/2016
7	Radiotherapy 11/2023 - 04/2011
1	Chemoradiotherapy 01/2021